Quizar 26.5 mg Tablet

Generic Name: Abiraterone Acetate
Brand Name: Quizar
Strength: 26.5 mg
Form: Film-coated Tablet
Pack Size: Commonly 120 tablets per bottle
Manufacturer: Everest Pharmaceuticals
Distributed by: NP Molecule

Indications:

Quizar (Abiraterone Acetate) is indicated for the treatment of:

• Metastatic castration-resistant prostate cancer (mCRPC)

• Metastatic high-risk castration-sensitive prostate cancer (mCSPC)
  Used in combination with prednisone or prednisolone, this therapy helps improve survival and delay disease progression.

Pharmacology:

Abiraterone is a selective inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase), an enzyme crucial for androgen biosynthesis.
By blocking CYP17, Abiraterone reduces testosterone production from:

• The testes

• The adrenal glands

• The tumor itself
  This leads to suppression of cancer cell growth in androgen-dependent prostate cancer.

Dosage & Administration:

• Recommended total daily dose: 1,000 mg Abiraterone Acetate, given as multiple tablets of 26.5 mg.

• Must be taken on an empty stomach (no food 2 hours before and 1 hour after).

• Prednisone 5 mg twice daily should be administered to prevent corticosteroid-related adverse effects.

• Dose adjustments may be needed for liver function or side effects.

Drug Interactions:

• Avoid strong CYP3A4 inducers (e.g., rifampin) and CYP2D6 substrates with narrow therapeutic index.

• Abiraterone may elevate liver enzymes; caution in hepatic impairment.

Contraindications:

• Known hypersensitivity to Abiraterone or tablet components.

• Contraindicated in women, especially during pregnancy due to risk of fetal harm.

Side Effects:

• Common: Fatigue, joint swelling, hypertension, fluid retention, low potassium.

• Serious: Hepatotoxicity, adrenal insufficiency, cardiac disorders (e.g., arrhythmias).

Pregnancy & Lactation:

• Contraindicated during pregnancy.

• Male patients should use effective contraception during and for 3 months after the last dose.

• Not intended for use in women.

Precautions & Warnings:

• Monitor liver function tests and serum potassium regularly.

• Blood pressure monitoring is recommended due to risk of hypertension.

• Risk of mineralocorticoid excess (fluid retention, hypokalemia).

Overdose Effects:

• Potential for increased adverse effects such as severe electrolyte disturbances or hepatic toxicity.

• Provide symptomatic treatment and supportive care.

Therapeutic Class:

• Hormonal Therapy

• Androgen Biosynthesis Inhibitor (CYP17 Inhibitor)

Storage Conditions:

• Store below 30°C.

• Keep dry and protect from light.

• Keep out of reach of children.